Request for Nominations of Individuals and Consumer Organizations for the Genetic Metabolic Diseases Advisory Committee, 86342-86343 [2023-27302]
Download as PDF
86342
Federal Register / Vol. 88, No. 238 / Wednesday, December 13, 2023 / Notices
rural and health professional shortage
areas and determining the effects of
personnel on access to the services of
such facilities in such areas;
determining whether there will be a
sufficient number of medical physicists
after October 1, 1999; and determining
the costs and benefits of compliance
with these requirements.
II. Criteria for Members
Persons nominated for membership as
consumer representatives on
committees or panels should meet the
following criteria: (1) demonstrate an
affiliation with and/or active
participation in consumer or
community-based organizations, (2) be
able to analyze technical data, (3)
understand research design, (4) discuss
benefits and risks, and (5) evaluate the
safety and efficacy of products under
review. The consumer representative
should be able to represent the
consumer perspective on issues and
actions before the advisory committee;
serve as a liaison between the
committee and interested consumers,
associations, coalitions, and consumer
organizations; and facilitate dialogue
with the advisory committees on
scientific issues that affect consumers.
khammond on DSKJM1Z7X2PROD with NOTICES
III. Selection Procedures
Selection of members representing
consumer interests is conducted
through procedures that include the use
of organizations representing the public
interest and public advocacy groups.
These organizations recommend
nominees for the Agency’s selection.
Representatives from the consumer
health branches of Federal, State, and
local governments also may participate
in the selection process. Any consumer
organization interested in participating
in the selection of an appropriate voting
or nonvoting member to represent
consumer interests should send a letter
stating that interest to FDA (see
ADDRESSES) within 30 days of
publication of this document.
Within the subsequent 45 days, FDA
will compile a list of consumer
organizations that will participate in the
selection process and will forward to
each such organization a ballot listing at
least two qualified nominees selected by
the Agency based on the nominations
received, together with each nominee’s
current curriculum vitae or re´sume´.
Ballots are to be filled out and returned
to FDA within 30 days. The nominee
receiving the highest number of votes
ordinarily will be selected to serve as
the member representing consumer
interests for that particular advisory
committee or panel.
VerDate Sep<11>2014
16:54 Dec 12, 2023
Jkt 262001
IV. Nomination Procedures
Any interested person or organization
may nominate one or more qualified
persons to represent consumer interests
on the Agency’s advisory committees or
panels. Self-nominations are also
accepted. Nominations must include a
current, complete re´sume´ or curriculum
vitae for each nominee and a signed
copy of the Acknowledgement and
Consent form available at the FDA
Advisory Nomination Portal (see
ADDRESSES), and a list of consumer or
community-based organizations for
which the candidate can demonstrate
active participation.
Nominations must also specify the
advisory committee(s) or panel(s) for
which the nominee is recommended. In
addition, nominations must also
acknowledge that the nominee is aware
of the nomination unless selfnominated. FDA will ask potential
candidates to provide detailed
information concerning such matters as
financial holdings, employment, and
research grants and/or contracts to
permit evaluation of possible sources of
conflicts of interest. Members will be
invited to serve for terms of up to 4
years.
FDA will review all nominations
received within the specified
timeframes and prepare a ballot
containing the names of qualified
nominees. Names not selected will
remain on a list of eligible nominees
and be reviewed periodically by FDA to
determine continued interest. After
selecting qualified nominees for the
ballot, FDA will provide those
consumer organizations that are
participating in the selection process
with the opportunity to vote on the
listed nominees. Only organizations
vote in the selection process. Persons
who nominate themselves to serve as
voting or nonvoting consumer
representatives will not participate in
the selection process.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: December 8, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–27308 Filed 12–12–23; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–N–0008]
Request for Nominations of Individuals
and Consumer Organizations for the
Genetic Metabolic Diseases Advisory
Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
requesting nominations for a voting
consumer representative to serve on the
Genetic Metabolic Diseases Advisory
Committee. FDA is also requesting that
any consumer organizations interested
in participating in the selection of a
voting consumer representative to serve
on the Genetic Metabolic Diseases
Advisory Committee notify FDA in
writing. Nominees recommended to
serve as a voting consumer
representative may either be selfnominated or may be nominated by a
consumer organization. Nominations
will be accepted for the current vacancy
effective with this notice. FDA seeks to
include the views of members of all
gender groups, members of all racial and
ethnic groups, and individuals with and
without disabilities on its advisory
committees and, therefore, encourages
nominations of appropriately qualified
candidates from these groups.
DATES: Any consumer organization
interested in participating in the
selection of an appropriate voting
member to represent consumer interests
on the Genetic Metabolic Diseases
Advisory Committee may send a letter
or email stating that interest to FDA (see
ADDRESSES) by February 12, 2024 for
vacancy listed in this notice.
Concurrently, nomination materials for
prospective candidates should be sent to
FDA (see ADDRESSES) by February 12,
2024. Nominations will be accepted for
current vacancy.
ADDRESSES: All statements of interest
from consumer organizations interested
in participating in the selection process
should be submitted electronically to
ACOMSSubmissions@fda.hhs.gov or by
mail to Advisory Committee and
Management Staff, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5122, Silver Spring,
MD 20993–0002.
Consumer representative nominations
should be submitted electronically by
logging into the FDA Advisory
Committee Membership Nomination
SUMMARY:
E:\FR\FM\13DEN1.SGM
13DEN1
Federal Register / Vol. 88, No. 238 / Wednesday, December 13, 2023 / Notices
Portal: https://www.accessdata.fda.gov/
scripts/FACTRSPortal/FACTRS/
index.cfm or by mail to Advisory
Committee Oversight and Management
Staff, 10903 New Hampshire Ave., Bldg.
32, Rm. 5122, Silver Spring, MD 20993–
0002. Additional information about
becoming a member of an FDA advisory
committee can also be obtained by
visiting FDA’s website at https://
www.fda.gov/AdvisoryCommittees/
default.htm.
FOR FURTHER INFORMATION CONTACT:
For questions relating to participation
in the selection process: Kimberly
Hamilton, Advisory Committee
Oversight and Management Staff, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 5122,
Silver Spring, MD 20993–0002, 301–
796–8220, kimberly.hamilton@
fda.hhs.gov.
For questions relating to the Genetic
Metabolic Diseases Advisory Committee:
Moon Choi, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, 301–796–2894,
GEMDAC@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is
requesting nominations for a voting
consumer representative on the Genetic
Metabolic Diseases Advisory
Committee. Elsewhere in this Federal
Register, FDA is publishing separate
documents regarding:
1. Genetic Metabolic Diseases Advisory
Committee; Notice of Establishment
2. Request for Nominations for Voting
Members on a Public Advisory
Committee: Genetic Metabolic
Diseases Advisory Committee
3. Request for Nominations of
Individuals and Industry
Organizations for the Genetic
Metabolic Diseases Advisory
Committee
khammond on DSKJM1Z7X2PROD with NOTICES
I. Function and General Description of
the Committee Duties
Genetic Metabolic Diseases Advisory
Committee
The Committee reviews and evaluates
data on the safety and effectiveness of
marketed and investigational human
drug and biologic products for use in
the treatment of genetic metabolic
diseases and makes appropriate
recommendations to the Commissioner
of Food and Drugs.
II. Criteria for Members
Persons nominated for membership as
a consumer representative on this
committee should meet the following
criteria: (1) demonstrate an affiliation
with and/or active participation in
VerDate Sep<11>2014
16:54 Dec 12, 2023
Jkt 262001
consumer or community-based
organizations, (2) be able to analyze
technical data, (3) understand research
design, (4) discuss benefits and risks,
and (5) evaluate the safety and efficacy
of products under review. The
consumer representative should be able
to represent the consumer perspective
on issues and actions before the
advisory committee; serve as a liaison
between the committee and interested
consumers, associations, coalitions, and
consumer organizations; and facilitate
dialogue with the advisory committees
on scientific issues that affect
consumers.
III. Selection Procedures
Selection of members representing
consumer interests is conducted
through procedures that include the use
of organizations representing the public
interest and public advocacy groups.
These organizations recommend
nominees for the Agency’s selection.
Representatives from the consumer
health branches of Federal, State, and
local governments also may participate
in the selection process. Any consumer
organization interested in participating
in the selection of an appropriate voting
member to represent consumer interests
should send a letter stating that interest
to FDA (see ADDRESSES) within 30 days
of publication of this document.
Within the subsequent 60 days, FDA
will compile a list of consumer
organizations that will participate in the
selection process and will forward to
each such organization a ballot listing at
least two qualified nominees selected by
the Agency based on the nominations
received, together with each nominee’s
current curriculum vitae or re´sume´.
Ballots are to be filled out and returned
to FDA within 30 days. The nominee
receiving the highest number of votes
ordinarily will be selected to serve as
the member representing consumer
interests for that particular advisory
committee.
IV. Nomination Procedures
Any interested person or organization
may nominate one or more qualified
persons to represent consumer interests
on the Genetic Metabolic Diseases
Advisory Committee with the exception
of the following: Individuals who are
not U.S. citizens or nationals cannot be
appointed as advisory committee
members (42 U.S.C. 217(a)) in FDA.
Self-nominations are also accepted.
Nominations must include a current,
complete re´sume´ or curriculum vitae for
each nominee, including current
business and/or home address,
telephone number, and email address if
available; a signed copy of the
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
86343
Acknowledgment and Consent form
available at the FDA Advisory
Nomination Portal (see ADDRESSES); and
a list of consumer or community-based
organizations for which the candidate
can demonstrate active participation.
Nominations should also specify the
advisory committee for which the
nominee is recommended. In addition,
nominations must also acknowledge
that the nominee is aware of the
nomination, unless self-nominated. FDA
will ask potential candidates to provide
detailed information concerning such
matters related to financial holdings,
employment, and research grants and/or
contracts to permit evaluation of
possible sources of conflicts of interest.
Members will be invited to serve for
terms up to 4 years.
FDA will review all nominations
received within the specified
timeframes and prepare a ballot
containing the names of qualified
nominees. Names not selected will
remain on a list of eligible nominees
and be reviewed periodically by FDA to
determine continued interest. After
selecting qualified nominees for the
ballot, FDA will provide those
consumer organizations that are
participating in the selection process
with the opportunity to vote on the
listed nominees. Only organizations
vote in the selection process. Persons
who nominate themselves to serve as
voting consumer representatives will
not participate in the selection process.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. 1001 et seq.) and 21 CFR part 14,
relating to advisory committees.
Dated: December 7, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–27302 Filed 12–12–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–N–1506]
Methodological Challenges Related to
Patient Experience Data; Summary of
Received Comments
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a summary on the
comments received for the
‘‘Methodological Challenges Related to
SUMMARY:
E:\FR\FM\13DEN1.SGM
13DEN1
Agencies
[Federal Register Volume 88, Number 238 (Wednesday, December 13, 2023)]
[Notices]
[Pages 86342-86343]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-27302]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-N-0008]
Request for Nominations of Individuals and Consumer Organizations
for the Genetic Metabolic Diseases Advisory Committee
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is requesting
nominations for a voting consumer representative to serve on the
Genetic Metabolic Diseases Advisory Committee. FDA is also requesting
that any consumer organizations interested in participating in the
selection of a voting consumer representative to serve on the Genetic
Metabolic Diseases Advisory Committee notify FDA in writing. Nominees
recommended to serve as a voting consumer representative may either be
self-nominated or may be nominated by a consumer organization.
Nominations will be accepted for the current vacancy effective with
this notice. FDA seeks to include the views of members of all gender
groups, members of all racial and ethnic groups, and individuals with
and without disabilities on its advisory committees and, therefore,
encourages nominations of appropriately qualified candidates from these
groups.
DATES: Any consumer organization interested in participating in the
selection of an appropriate voting member to represent consumer
interests on the Genetic Metabolic Diseases Advisory Committee may send
a letter or email stating that interest to FDA (see ADDRESSES) by
February 12, 2024 for vacancy listed in this notice. Concurrently,
nomination materials for prospective candidates should be sent to FDA
(see ADDRESSES) by February 12, 2024. Nominations will be accepted for
current vacancy.
ADDRESSES: All statements of interest from consumer organizations
interested in participating in the selection process should be
submitted electronically to [email protected] or by mail to
Advisory Committee and Management Staff, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 32, Rm. 5122, Silver Spring, MD 20993-
0002.
Consumer representative nominations should be submitted
electronically by logging into the FDA Advisory Committee Membership
Nomination
[[Page 86343]]
Portal: https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm or by mail to Advisory Committee Oversight and Management
Staff, 10903 New Hampshire Ave., Bldg. 32, Rm. 5122, Silver Spring, MD
20993-0002. Additional information about becoming a member of an FDA
advisory committee can also be obtained by visiting FDA's website at
https://www.fda.gov/AdvisoryCommittees/default.htm.
FOR FURTHER INFORMATION CONTACT:
For questions relating to participation in the selection process:
Kimberly Hamilton, Advisory Committee Oversight and Management Staff,
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm.
5122, Silver Spring, MD 20993-0002, 301-796-8220,
[email protected].
For questions relating to the Genetic Metabolic Diseases Advisory
Committee: Moon Choi, Center for Drug Evaluation and Research, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993-0002, 301-796-2894, [email protected].
SUPPLEMENTARY INFORMATION: FDA is requesting nominations for a voting
consumer representative on the Genetic Metabolic Diseases Advisory
Committee. Elsewhere in this Federal Register, FDA is publishing
separate documents regarding:
1. Genetic Metabolic Diseases Advisory Committee; Notice of
Establishment
2. Request for Nominations for Voting Members on a Public Advisory
Committee: Genetic Metabolic Diseases Advisory Committee
3. Request for Nominations of Individuals and Industry Organizations
for the Genetic Metabolic Diseases Advisory Committee
I. Function and General Description of the Committee Duties
Genetic Metabolic Diseases Advisory Committee
The Committee reviews and evaluates data on the safety and
effectiveness of marketed and investigational human drug and biologic
products for use in the treatment of genetic metabolic diseases and
makes appropriate recommendations to the Commissioner of Food and
Drugs.
II. Criteria for Members
Persons nominated for membership as a consumer representative on
this committee should meet the following criteria: (1) demonstrate an
affiliation with and/or active participation in consumer or community-
based organizations, (2) be able to analyze technical data, (3)
understand research design, (4) discuss benefits and risks, and (5)
evaluate the safety and efficacy of products under review. The consumer
representative should be able to represent the consumer perspective on
issues and actions before the advisory committee; serve as a liaison
between the committee and interested consumers, associations,
coalitions, and consumer organizations; and facilitate dialogue with
the advisory committees on scientific issues that affect consumers.
III. Selection Procedures
Selection of members representing consumer interests is conducted
through procedures that include the use of organizations representing
the public interest and public advocacy groups. These organizations
recommend nominees for the Agency's selection. Representatives from the
consumer health branches of Federal, State, and local governments also
may participate in the selection process. Any consumer organization
interested in participating in the selection of an appropriate voting
member to represent consumer interests should send a letter stating
that interest to FDA (see ADDRESSES) within 30 days of publication of
this document.
Within the subsequent 60 days, FDA will compile a list of consumer
organizations that will participate in the selection process and will
forward to each such organization a ballot listing at least two
qualified nominees selected by the Agency based on the nominations
received, together with each nominee's current curriculum vitae or
r[eacute]sum[eacute]. Ballots are to be filled out and returned to FDA
within 30 days. The nominee receiving the highest number of votes
ordinarily will be selected to serve as the member representing
consumer interests for that particular advisory committee.
IV. Nomination Procedures
Any interested person or organization may nominate one or more
qualified persons to represent consumer interests on the Genetic
Metabolic Diseases Advisory Committee with the exception of the
following: Individuals who are not U.S. citizens or nationals cannot be
appointed as advisory committee members (42 U.S.C. 217(a)) in FDA.
Self-nominations are also accepted. Nominations must include a current,
complete r[eacute]sum[eacute] or curriculum vitae for each nominee,
including current business and/or home address, telephone number, and
email address if available; a signed copy of the Acknowledgment and
Consent form available at the FDA Advisory Nomination Portal (see
ADDRESSES); and a list of consumer or community-based organizations for
which the candidate can demonstrate active participation.
Nominations should also specify the advisory committee for which
the nominee is recommended. In addition, nominations must also
acknowledge that the nominee is aware of the nomination, unless self-
nominated. FDA will ask potential candidates to provide detailed
information concerning such matters related to financial holdings,
employment, and research grants and/or contracts to permit evaluation
of possible sources of conflicts of interest. Members will be invited
to serve for terms up to 4 years.
FDA will review all nominations received within the specified
timeframes and prepare a ballot containing the names of qualified
nominees. Names not selected will remain on a list of eligible nominees
and be reviewed periodically by FDA to determine continued interest.
After selecting qualified nominees for the ballot, FDA will provide
those consumer organizations that are participating in the selection
process with the opportunity to vote on the listed nominees. Only
organizations vote in the selection process. Persons who nominate
themselves to serve as voting consumer representatives will not
participate in the selection process.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. 1001 et seq.) and 21 CFR part 14, relating to advisory
committees.
Dated: December 7, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-27302 Filed 12-12-23; 8:45 am]
BILLING CODE 4164-01-P